Production of proteins in glutamine-free cell culture media

What is this patent about?

’003 is related to the field of mammalian cell culture and the large-scale recombinant production of therapeutic proteins. Specifically, it addresses the challenges of maintaining high cell viability and protein yield in Chinese Hamster Ovary (CHO) systems, where the accumulation of toxic metabolic byproducts like ammonia often limits culture longevity and final product concentration.

The underlying idea behind ’003 is that the traditional reliance on L-glutamine as a primary nitrogen and energy source is counterproductive due to its role as the chief precursor for ammonia. By completely eliminating glutamine from the production phase and replacing its metabolic function with asparagine supplementation, the process bypasses the standard ammonia-generating pathway, thereby reducing cytotoxicity and forcing the cells into a more efficient metabolic state for protein synthesis.

The claims of ’003 focus on a specific manufacturing process for producing antibodies using CHO host cells. The core requirement of the independent claim is the use of a glutamine-free production culture medium that has been specifically fortified with asparagine during the production phase of the cell culture cycle.

In practice, the invention works by transitioning the cell culture from a growth phase to a production phase where the nutrient environment is strictly controlled. While standard media formulations typically include 1 to 20 mM of glutamine, this method utilizes a medium where glutamine is omitted entirely, and asparagine is added—ideally at concentrations between 2.5 mM and 15 mM—to provide the necessary amide groups for cellular function without the associated ammonia buildup.

This approach differs from prior methods that either accepted high ammonia levels or attempted to use glutamate as a substitute, which often resulted in slower growth rates. By leveraging the unexpected synergy of a glutamine-free environment and asparagine enrichment, the process achieves increased specific productivity and higher final titers for complex glycoproteins, such as monoclonal antibodies and immunoadhesins, compared to conventional glutamine-containing processes.